A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 16, 2026 Show 4 more changesShow less
    • Study sites: 181 to 193
    • Eligibility criteria revised
    • Secondary endpoints: 7 to 12
    • Publications: details revised at 2 of 2 entries
  2. Re-verified, no change to tracked fieldsv48
  3. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Jul 8, 2025 to Jul 7, 2025
    • Site details revised at 3 of 181 sites
    v47
  4. Study sites: 170 to 181v46
  5. Enrollment target: estimated 1440 to confirmed 1334
    • Study sites: 192 to 170
    • Primary completion date changed from estimate of Feb 19, 2025 to Feb 24, 2025
    • Study completion date: Apr 29, 2025 to Jul 8, 2025
    v45
Show 43 earlier versionsHide 43 earlier versions
  1. Study sites: 194 to 192v44
  2. Study sites: 196 to 194v43
  3. Study sites: 199 to 196v42
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 219 to 199
    v41
  5. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 205 to 219
    v40
  6. Study sites: 207 to 205v39
  7. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 219 to 207
    • Primary completion date: Jan 1, 2025 to Feb 19, 2025
    • Study completion date: Mar 1, 2025 to Apr 29, 2025
    v38
  8. Site details revised at 11 of 219 sitesv37
  9. Study sites: 217 to 219v36
  10. Study sites: 216 to 217v35
  11. Study sites revised (216)v34
  12. Study sites: 215 to 216v33
  13. Site details revised at 1 of 215 sitesv32
  14. Enrollment target: 1290 to 1440
    • Study sites revised (215)
    v31
  15. Study sites revised (215)v30
  16. Study sites: 212 to 215v29
  17. Re-verified, no change to tracked fieldsv28
  18. Study sites: 210 to 212v27
  19. Study sites: 209 to 210v26
  20. Re-verified, no change to tracked fieldsv25
  21. Site details revised at 7 of 209 sitesv24
  22. Study sites: 205 to 209v23
  23. Study sites: 204 to 205v22
  24. Primary completion date: May 1, 2024 to Jan 1, 2025
    • Enrollment target: 930 to 1290
    • Study completion date: Aug 1, 2024 to Mar 1, 2025
    • Secondary endpoints: 6 to 7
    v21
  25. Study sites: 201 to 204v20
  26. Study sites: 200 to 201v19
  27. Study sites: 195 to 200v18
  28. Study sites: 190 to 195v17
  29. Study sites: 189 to 190v16
  30. Study sites: 182 to 189v15
  31. Study sites: 171 to 182v14
  32. Study sites: 153 to 171v13
  33. Study sites: 136 to 153v12
  34. Study sites: 126 to 136v11
  35. Study sites: 101 to 126v10
  36. Study sites: 53 to 101v9
  37. Study sites: 32 to 53v8
  38. Study sites: 27 to 32v7
  39. Study sites: 23 to 27v6
  40. Study sites: 16 to 23v5
  41. Study sites: 234 to 16v4
  42. Study sites: 225 to 234
    • Start date changed from estimate of Oct 1, 2021 to Oct 5, 2021
    v3
  43. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 1, 2021 to Oct 1, 2021
    • Study sites: 212 to 225
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
367 trials monitored
See 31 trials at risk
COPD
1,120 trials monitored
See 36 trials at risk
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Trial Details
NCT Number NCT05037929
Lead Sponsor Genentech, Inc.
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 1,334 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov